Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 974155103 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 3 | 0.5% |
8/14/2026
Event 6/30/2026
|
|
|
Lone Pine Capital LLC
13G/A
Amendment 1
|
0% |
5/15/2026
Event 3/31/2026
|
|
| Lone Pine Capital LLC | 0% | ||
| David F. Craver | 0% | ||
| Brian F. Doherty | 0% | ||
| Kelly A. Granat | 0% | ||
| Stephen F. Mandel, Jr. | 0% | ||
| Kerry A. Tyler | 0% | ||
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 2 | 6.6% |
5/15/2026
Event 3/31/2026
|
|
| Massachusetts Financial Services Co /MA/ 13G/A Amendment 1 | 4.8% |
5/14/2026
Event 3/31/2026
|
|
|
Darsana Capital Partners LP
13G
|
5.5% |
5/12/2026
Event 5/5/2026
|
|
| Darsana Capital Partners LP | 5.5% | ||
| Darsana Capital Partners GP LLC | 5.5% | ||
| Darsana Master Fund LP | 5.5% | ||
| Darsana Capital GP LLC | 5.5% | ||
| Anand Desai | 5.5% | ||
|
FMR LLC
13G/A
Amendment 1
|
14.2% |
5/7/2026
Event 4/30/2026
|
|
| FMR LLC | 14.2% | ||
| Abigail P. Johnson | 14.2% | ||
|
FMR LLC
13G
|
7.8% |
5/6/2026
Event 3/31/2026
|
|
| FMR LLC | 7.8% | ||
| Abigail P. Johnson | 7.8% | ||
| Vanguard Capital Management LLC 13G | 5.3% |
4/30/2026
Event 3/31/2026
|
|
| Vanguard Group Inc 13G/A Amendment 11 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
American Century Investment Management, Inc.
13G/A
Amendment 1
|
4.1% |
2/13/2026
Event 12/31/2025
|
|
| American Century Investment Management, Inc. | 4.1% | ||
| American Century Companies, Inc. | 4.1% | ||
| Stowers Institute for Medical Research | 4.1% | ||
| Massachusetts Financial Services Co /MA/ 13G | 5.1% |
1/28/2026
Event 12/31/2025
|
|
|
Lone Pine Capital LLC
13G
|
5.3% |
9/26/2025
Event 9/19/2025
|
|
| Lone Pine Capital LLC | 5.3% | ||
| David F. Craver | 5.3% | ||
| Brian F. Doherty | 5.3% | ||
| Kelly A. Granat | 5.3% | ||
| Stephen F. Mandel, Jr. | 5.3% | ||
| Kerry A. Tyler | 5.3% | ||
| Price T Rowe Associates Inc /MD/ 13G/A Amendment 1 | 7.7% |
8/14/2025
Event 6/30/2025
|
|
|
American Century Investment Management, Inc.
13G
|
5.6% |
8/14/2025
Event 6/30/2025
|
|
| American Century Investment Management, Inc. | 5.6% | ||
| American Century Companies, Inc. | 5.6% | ||
| Stowers Institute for Medical Research | 5.6% | ||
| Price T Rowe Associates Inc /MD/ 13G | 5.9% |
5/14/2025
Event 3/31/2025
|
|
| BlackRock, Inc. 13G/A Amendment 11 | 9.6% |
4/17/2025
Event 3/31/2025
|
|
| BlackRock, Inc. 13G/A Amendment 10 | 12.2% |
2/5/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 12 | 9.96 k | $1.05 M |
| 2026 Q2 | 465 | 39.3 M | $5.89 B |
| 2026 Q1 | 437 | 32.9 M | $5.11 B |
| 2025 Q4 | 480 | 36.5 M | $8.72 B |
| 2025 Q3 | 461 | 34.6 M | $8.70 B |
| 2025 Q2 | 516 | 31.8 M | $10.7 B |
| 2025 Q1 | 478 | 30.3 M | $6.83 B |
| 2024 Q4 | 494 | 30.0 M | $8.51 B |
| 2024 Q3 | 534 | 30.0 M | $12.4 B |
| 2024 Q2 | 504 | 30.4 M | $12.8 B |
| 2024 Q1 | 477 | 31.2 M | $11.4 B |
| 2023 Q4 | 423 | 31.8 M | $8.17 B |
| 2023 Q3 | 369 | 31.3 M | $5.63 B |
| 2023 Q2 | 395 | 30.9 M | $6.18 B |
| 2023 Q1 | 374 | 32.8 M | $6.02 B |
| 2022 Q4 | 357 | 35.6 M | $4.91 B |
| 2022 Q3 | 328 | 34.4 M | $4.32 B |
| 2022 Q2 | 273 | 35.9 M | $2.69 B |
| 2022 Q1 | 301 | 32.7 M | $3.84 B |
| 2021 Q4 | 306 | 32.1 M | $5.55 B |
| 2021 Q3 | 303 | 32.2 M | $5.28 B |
| 2021 Q2 | 300 | 31.8 M | $5.01 B |
| 2021 Q1 | 310 | 31.8 M | $4.05 B |
| 2020 Q4 | 344 | 31.7 M | $4.20 B |
| 2020 Q3 | 341 | 31.0 M | $4.23 B |
| 2020 Q2 | 311 | 32.1 M | $4.46 B |
| 2020 Q1 | 252 | 36.0 M | $2.87 B |
| 2019 Q4 | 249 | 32.3 M | $2.78 B |
| 2019 Q3 | 256 | 31.8 M | $2.75 B |
| 2019 Q2 | 256 | 33.1 M | $3.14 B |
| 2019 Q1 | 253 | 33.1 M | $2.52 B |
| 2018 Q4 | 239 | 32.7 M | $2.10 B |
| 2018 Q3 | 231 | 33.4 M | $2.28 B |
| 2018 Q2 | 221 | 34.8 M | $1.81 B |
| 2018 Q1 | 200 | 35.5 M | $1.68 B |
| 2017 Q4 | 175 | 35.3 M | $1.38 B |
| 2017 Q3 | 153 | 39.7 M | $1.32 B |
| 2017 Q2 | 142 | 39.0 M | $1.20 B |
| 2017 Q1 | 135 | 36.4 M | $1.03 B |
| 2016 Q4 | 129 | 35.0 M | $1.04 B |
| 2016 Q3 | 97 | 24.6 M | $722 M |
| 2016 Q2 | 83 | 16.9 M | $461 M |
| 2016 Q1 | 81 | 16.1 M | $364 M |
| 2015 Q4 | 68 | 10.7 M | $243 M |
| 2015 Q3 | 68 | 8.40 M | $201 M |
| 2015 Q2 | 56 | 5.89 M | $167 M |